Articles

To request a copy of an article listed below, please use the Contact Us form.

Juarez, J.C., Manuia, M., Burnett, M.E., Betancourt, O., Boivin, B., Shaw, D.E., Tonks, N.K., Mazar, A.P., Doñate, F. (2008) “Superoxide dismutase 1 (SOD1) is essential for H₂O₂-mediated oxidation and inactivation of phosphatases in growth factor signaling” Proc. Natl. Acad. Sci., USA, 105(20):7147-7152.

Doñate, F., Juarez, J.C., Burnett M.E., Manuia, M.M., Guan, X., Shaw, D.E., Smith, E.L.P., Timucin, C., Braunstein, M.J., Batuman, O.A., Mazar, A.P. (2008) “Identification of biomarkers for the antiangiogenic and antitumor activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224). Br J Cancer, 98(4): 776-783.

Li Y, Parry G, Chen L, Callahan JA, Shaw DE, Meehan EJ, Mazar AP, Huang M (2007). An Anti-urokinase Plasminogen Activator Receptor (uPAR) Antibody: Crystal Structure and Binding Epitope. J Mol Biol. 365: 1117-1129.

Chidlow, JH, Langston, W, Greer, JJ, Ostanin, D, Abdelbaqi, M, Houghton, J, Senthilkumar, A, Shukla, D, Mazar, AP, Grisham, MB and Kevil, CG (2006). “Differential Angiogenic Regulation of Experimental Colitis.” Am J Pathol 169: 2014-2020.

Barinka C, Parry G, Callahan J, Shaw DE, Kuo A, Bdeir K, Cines DB, Mazar A, Lubkowski J (2006). Structural Basis of Interaction between Urokinase-type Plasminogen Activator and its Receptor. J Mol Biol. 363:482-95.

Idell S, Allen T, Chen S, Koenig K, Mazar A, Azghani A. Intrapleural Activation, Processing, Efficacy and Duration of Protection of Single Chain Urokinase in Evolving Tetracycline-induced Pleural Injury in Rabbits. Am J Physiol Lung Cell Mol Physiol. 2006 Sep 15.

Danese S, Sans M, Spencer D, Beck I, Donate F, Plunkett M, de la Motte C, Redline R, Shaw D, Levine A, Mazar A, Fiocchi C. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut. 2006 Dec 14; [Epub ahead of print].

Allan, A.L., Gladstone, P.L., Price, M.L., Hopkins, S.A., Juarez, J.C., Donate, F., Ternansky, R.J., Shaw, D.E., Ganem, B., Li, Y., Wang, W., Ealick, S. (2006) "Synthesis and Evaluation of Multisubstrate Bicyclic Pyrimidine Nucleoside Inhibitors of Human Thymidine Phosphorylase" J Med Chem 49(26):7807-7815.

Khalili, P., Arakelian, A., Chen, G., Plunkett, M.L., Beck, I., Parry, G.C., Doñate, F., Shaw, D.E., Mazar, A.P. and Rabbani, S.A. (2006). “A non-RGD based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo.” Mol Cancer Ther 5: 2271-2280.

Juarez, J.C., Betancourt, O., Pirie-Shepherd, S.R., Guan, X., Price, M.P., Shaw, D.E., Mazar, A.P., Doñate, F. (2006) "Copper Binding by Tetrathiomolybdate Attenuates Angiogenesis and Tumor Cell Proliferation through the Inhibition of Superoxide Dismutase 1." Clin Cancer Res 12:4974-4982.

Cianfrocca, M.E., Kimmel, K.A., Gallo, J.,Cardoso, T., Brown, M.M., Hudes, G., Lewis, N., Weiner, L., Lam, G.N., Brown, S.C., Shaw, D.E., Mazar, A.P. and Cohen, R.B. (2006). “Phase I Trial Of The Antiangiogenic Peptide ATN 161 (Ac-PHSCN-NH2)), a Beta Integrin Antagonist, In Patients With Solid Tumors.” Br J Cancer 94:1621-6.

Tarui, T., Akakura, N., Majumdar, M., Andronicos, N., Takagi, J., Mazar, A.P., Bdeir, K., Kuo, A., Yarovoi, S.V., Cines, D.B. and Takada, Y. (2006) “Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alphavbeta3 induces signal transduction and enhances plasminogen activation." Thromb Haemost. 95: 524-34.

Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L, Furie B, Furie BC, Cines DB, Huang M. (2006) "Structure of human urokinase plasminogen activator in complex with its receptor." Science 311:656-9.

Li, Y., Shi, X., Parry, G., Chen, L., Callahan, J.A., Mazar, A.P. and Huang, M. (2005) “Optimization of crystals of an inhibitory antibody of urokinase plasminogen activator receptor (uPAR) with hydrogen peroxide and low protein concentration.” Protein and Peptide Lett. 12; 655-658.

F. Doñate. (2005) "Anti-angiogenic therapy in cancer." Drugs of the Future 30 (7): 695-707.

Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP, Ellis LM (2005) " Targeting of Urokinase Plasminogen Activator Receptor in Human Pancreatic Carcinoma Cells Inhibits c-Met- and Insulin-like Growth Factor-I Receptor-Mediated Migration and Invasion and Orthotopic Tumor Growth in Mice." Cancer Res. 65:7775-7781.

Huang, M., Mazar, A.P., Parry, G.C., Kuo, A. and Cines, D.B. (2005) “Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino terminal fragment (1-143).” Acta. Crystallograph D61: 697-700.

Bauer, T.W., Fan, F., Liu, W., Johnson, M., Parikh, N.U., Parry, G.C., Callahan, J., Mazar, A.P., Gallick, G. and Ellis, L.M. (2005) “Insulin-like growth factor-1-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor": Annals of Surgery 241: 748-758.

Parry, G.C., Doñate, F., Plunkett, M.L., Shaw, D.E., Pirie-Shepherd, S. and Mazar, A. (2005). "Integrins: Novel targets for the treatment of bone metastasis." In: Cancer Drug Discovery and Development. Bone metastasis: Experimental and Clinical Therapeutics. G. Singh and S.A. Rabbani, eds. Humana Press: 201-227.

Doñate, F., McCrae, K., Shaw, D.E. and Mazar, A.P. (2004) "Extracellular Tropomyosin: A Novel Common Pathway Target for Anti-Angiogenic Therapy" Current Cancer Drug Targets 4:543-553.

Doñate, F., Juarez, J.C., Guan, X., Shipulina, N.V., Plunkett, M.L., Tel-Tsur, Z., Shaw, D.E., Morgan, W.T., Mazar, A.P. (2004) "Peptides Derived from the Histidine-Proline Domain of the Histidine-Proline-Rich Glycoprotein Bind to Tropomyosin and Have Antiangiogenic and Antitumor Activities" Cancer Research 64:5812-5817.

Guan, X., Juarez, J.C., Qi, X, Shipulina, N.V., Shaw, D.E., Morgan, W.T., McCrae, K.R., Mazar, A.P., Donate, F. (2004) "Histidine-Proline Rich Glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells" Thrombosis and Haemostasis 92: 403-12.

Rabbani, S.A., Shukeir, N., Mazar, A.P (2004). “Prostate Cancer: Models for Developing Novel Therapeutic Approaches.” in Bone Metastasis and Molecular Mechanisms: G. Singh and F.W. Orr (Eds.), Kluwer Academic Publishers (Boston): 163-186.

Tarui T, Andronicos N, Czerkay RP, Mazar AP, Bdeir K, Parry GC, Kuo A, Loskutoff DJ, Cines DB, Takada YJ (2003) “Critical role of integrin alpha 5beta 1 in urokinase (uPA) /urokinase receptor (uPAR, CD87) signaling.” J Biol Chem 278: 29863-29872.

Bdeir, K, Kuo, A, Sachais, BS, Ruxl, AH, Bdeir, Y, Mazar, AP, Higazi, AA-R and Cines, DB (2003) “The kringle stabilizes urokinase binding to the urokinase receptor.” Blood 102: 3600-3608.

Stoeltzing, O, Liu, W, Reinmuth N, Fan, F, Parry, GC, Parikh, A A, McCarty, MF, Bucana, CD, Mazar, AP, and Ellis, LM (2003) "Inhibition of Integrin a5b1 Function with a Small Peptide (ATN-161) Plus Continuous 5-FU Infusion Reduces Colorectal Liver Metastases and Improves Survival in Mice" Int. J. Cancer 104:496-503.

Price, MLP, Guida, WC, Jackson, TE, Nydick, JA, Gladstone, PL, Juarez, JC, Donate, F, Ternansky, RJ (2003) "Design of Novel N-(2,4-Dioxo-1,2,3,4-tetrahydro-thieno[3,2- d]pyrimidin-7-yl)-guanidines as Thymidine Phosphorylase Inhibitors, and Flexible Docking to a Homology Model" Bioorg. Med. Chem. Lett. 13:107-110.

Zhang, J-C, Donate, F, Qi, X, Ziats, NP, Juarez, JC, Mazar, AP, Pang, Y-P, McCrae, KR, (2002) "The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin" Proc. Natl. Acad. Sci., USA, 99(19):12224-12229.

Juarez, JC, Guan, X, Shipulina, NV, Plunkett, ML, Parry, GC, Shaw, DE, Zhang, J-C, Rabbani, SA, McCrae, KR, Mazar, AP, Morgan, WT, and Donate, F (2002) "Histidine-Proline-rich Glycoprotein Has Potent Antiangiogenic Activity Mediated through the Histidine-Proline-rich Domain" Cancer Research 62:5344-5350.

Ding, L, Donate, F, Parry, GCN, Guan, X, Mahers, P, Levin, EG (2002) "Inhibition of Cell Migration and Angiogenesis by the Amino-terminal Fragment of 24kD Basic Fibroblast Growth Factor" J. Biol. Chem., 277:31056-31061.

Zhang, J-C, Qi, X, Juarez, J, Plunkett, M, Donate, F, Sakthivel, R, Mazar, AP, McCrae, KR (2002) "Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides" Can. J. Physiol. Pharmacol. 80(2):85-90.

Mazar, AP (2001) "The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer." Anti-cancer Drugs 12: 387-400.

Al-Atrash, G, Kitson, R, Xue, Y, Mazar, A, Kim, M and Goldfarb, R (2001) "uPA and uPAR Contribute to NK Cell Invasion Through the Extracellular Matrix" Anticancer Research 21: 1-8.

Rabbani, SA and Mazar, AP (2001) "The Role of the Plasminogen Activation System in Angiogenesis and Metastasis" Surg. Oncol. Clin. N. America 10(2): 393-416.

Tarui, T, Mazar, AP, Cines, DB, Takada, T (2001) "Urokinase Receptor (uPAR/CD87) is a Genuine Ligand for Integrins and Mediates Cell-Cell Interaction" J. Biol. Chem. 276: 3983-3990.

Zhang, J-C, Claffey, K, Sakthivel, R, Darzynkiewicz, Z, Shaw, DE, Leal, J, Wang, Y-C, Lu, F-M and McCrae, KR (2000) "Two-Chain High Moleculer Weight Kininogen Induces Endothelial Cell Apoptosis and Inhibits Angiogenesis: Partial Activity Within Domain 5" FASEB J. 14: 2589-2600.